ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Ocular Therapeutix Inc

Ocular Therapeutix Inc (OCUL)

9,85
-0,27
(-2,62%)
Fermé 25 Juin 10:00PM
9,90
0,05
( 0,51% )
Avant marché: 12:33PM

Ocular Therapeutix Inc (OCUL) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
9,90
( 0,51% )
Prix Achat
9,75
Prix Vente
9,90
Volume échangé
1 007
0,00 Fourchette du Jour 0,00
6,30 Plage de 52 semaines 16,44
Cap du marché
Clôture Veille
9,85
Ouverture
-
Dernière Transaction
300
@
9.9
(formt)
Dernière heure de transaction
12:06:44
Volume financier
-
VWAP
-
Volume moyen (3 m)
US$ 3 132 874
Actions en circulation
218 960 358
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-6,88
Bénéfice par action (BPA)
-1,45
Chiffre d'affairess (LTM)
52,04M
Bénéfice net (LTM)
-290,5M

À propos de Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthal... Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
Siège social
Bedford, United States
Fondé
2026
Ocular Therapeutix Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker OCUL. Le dernier cours de clôture d'Ocular Therapeutix était de US$9,85. Au cours de la dernière année, les actions de Ocular Therapeutix ont été négociées dans une fourchette de prix de US$ 6,30 à US$ 16,44.

Ocular Therapeutix compte actuellement 218 960 358 actions en circulation. La capitalisation boursière d'Ocular Therapeutix est de US$2,17 milliard. Ocular Therapeutix a un ratio cours/bénéfice (ratio PE) de -6.88.

OCUL Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.1-11010.6159.3741994799.77749066CS
41.416.47058823538.510.6158.07130089539.15696802CS
121.8122.37330037088.0910.6157.8630395339.07940928CS
26-2.76-21.800947867312.6613.036.345677979.23149996CS
520.818.910891089119.0916.446.3364268510.37024496CS
1565.07104.9689440994.8316.441.99522175168.81451335CS
260-4.79-32.607215793114.6916.441.99517001038.23084391CS

OCUL - Frequently Asked Questions (FAQ)

What is the current Ocular Therapeutix Inc share price?
The current share price of Ocular Therapeutix Inc is US$ 9,90
How many Ocular Therapeutix Inc shares are in issue?
Ocular Therapeutix Inc has 218 960 358 shares in issue
What is the market cap of Ocular Therapeutix Inc?
The market capitalisation of Ocular Therapeutix Inc is USD 2,17B
What is the 1 year trading range for Ocular Therapeutix Inc share price?
Ocular Therapeutix Inc has traded in the range of US$ 6,30 to US$ 16,44 during the past year
What is the PE ratio of Ocular Therapeutix Inc?
The price to earnings ratio of Ocular Therapeutix Inc is -6,88
What is the cash to sales ratio of Ocular Therapeutix Inc?
The cash to sales ratio of Ocular Therapeutix Inc is 41,95
What is the registered address of Ocular Therapeutix Inc?
The registered address for Ocular Therapeutix Inc is 14 Crosby Drive, Bedford, Massachusetts, 01730
What is the Ocular Therapeutix Inc website address?
The website address for Ocular Therapeutix Inc is www.ocutx.com
Which industry sector does Ocular Therapeutix Inc operate in?
Ocular Therapeutix Inc operates in the Biotechnology & Life Sciences sector

OCUL Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock